Stockwinners Market Radar for March 27, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT KKR, Gaw Capital acquire Hyatt Regency Tokyo - KKR (KKR) and Gaw Capital Partners announced the signing of definitive agreements under which funds managed by KKR and Gaw Capital will acquire Hyatt Regency Tokyo (H), a luxury hotel located at the heart of Tokyo, from Odakyu Electric Railway Company. Kensuke Kudo, Director, Real Estate, at KKR, said, "This investment is a rare opportunity to acquire an iconic hotel in one of the most energetic districts in the world. As Japan emerges strongly from the pandemic as a leading travel destination, and domestic and international business travel bounce back, we see great potential to refurbish and to enhance the Hotel's offerings to both corporate and leisure guests while retaining its unique heritage. We are pleased to welcome Gaw Capital, with their hospitality expertise, as strategic partners here, which will enable us to tap into our collective strengths for the Hotel's transformation."

18:54 EDT AnaptysBio 'encouraged' by GSK phase 3 trial results - AnaptysBio (ANAB) announced that GSK (GSK) has shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly alone compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. These data from GSK's RUBY clinical trial are being shared in a European Society for Medical Oncology (ESMO) Virtual Plenary, presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer (25-28 March) in Tampa, Florida and published simultaneously in The New England Journal of Medicine. "We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors. The positive results from the RUBY trial represent a potential breakthrough for patients with primary advanced or recurrent endometrial cancer," said Daniel Faga, interim president and chief executive officer of AnaptysBio. "There is a potential significant royalty opportunity over time to AnaptysBio from Jemperli if this indication is approved, as well as from GSK's ongoing Phase 3 trials, including of dostarlimab in first line ovarian cancer and, in combination with cobolimab, a TIM-3 antagonist, in second line NSCLC."

18:22 EDT GSK says Phase III Ruby trial demonstrates Jemperli plus chemotherapy potential - GSK announced interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli plus standard-of-care chemotherapy followed by dostarlimab compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK said: "These positive results from the RUBY trial bring us one step closer to addressing the significant unmet needs of endometrial cancer patients and add to the growing body of evidence on dostarlimab, strengthening our belief in its potential to transform cancer treatment as a backbone immuno-oncology therapy." A statistically significant and clinically meaningful improvement in progression free survival was observed for dostarlimab plus carboplatin-paclitaxel in the mismatch repair deficient (dMMR)/microsatellite instability-high population and in the overall population versus placebo plus chemotherapy. The separation of the lines in the Kaplan-Meier curve below illustrates the significant reduction in risk of disease progression or death in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the dostarlimab plus chemotherapy treatment arm compared to the placebo plus chemotherapy treatment arm. The safety and tolerability profile of dostarlimab in combination with carboplatin-paclitaxel in the RUBY phase III trial was generally consistent with the known safety profiles of the individual agents. The most common (greater than45%) treatment-emergent adverse events (TEAEs) in both treatment arms in the dMMR/MSI-H and overall populations were nausea, alopecia and fatigue, as well as anaemia in the placebo plus chemotherapy arm in the dMMR/MSI-H population. Severe and serious TEAEs were approximately 10% higher in the dostarlimab plus carboplatin-paclitaxel arm compared with the placebo plus carboplatin-paclitaxel arm in the overall population. The nature and types of immune-related adverse events (irAEs) in the dostarlimab plus chemotherapy safety profile were consistent with the mechanism of action of dostarlimab and similar to those reported for other PD-(L)1 inhibitors. In the overall population, 38.2% of participants in the dostarlimab plus carboplatin-paclitaxel arm and 15.4% of participants in the placebo plus carboplatin-paclitaxel arm had irAEs assessed by the investigator as related to dostarlimab or placebo, respectively. The most frequently reported dostarlimab-related irAE categories were endocrinopathies (15.8% dostarlimab-related versus 3.3% placebo-related) and skin adverse reactions (14.1% dostarlimab-related versus 3.7% placebo-related). Discontinuation of dostarlimab or placebo due to a TEAE occurred in 17.4% of patients in the dostarlimab plus chemotherapy treatment arm and 9.3% of patients in the placebo plus chemotherapy treatment arm in the overall population.

17:53 EDT TD Synnex names John Henry chief accounting officer - According to a regulatory filing, on March 21, 2023, the Board of Directors of TD SYNNEX Corporation appointed John Henry, age 48, Senior Vice President, Chief Accounting Officer, as the Company's principal accounting officer. Mr. Henry joined the Company in 2015 as the Vice President of Corporate Accounting and has served as Senior Vice President, Chief Accounting Officer since November 2020. Prior to joining the Company, Mr. Henry served as a public accountant with both Arthur Andersen LLP and PricewaterhouseCoopers LLP, and as an accountant for DirecTV and AECOM. Mr. Henry is a graduate of California State University at Fresno with a degree in Accounting.

17:30 EDT Monopar Therapeutics Inc trading resumes

17:22 EDT Merck reports NRG-GY018 trial shows statistical significance, improvement in PFS - Merck announced results from the Phase 3 NRG-GY018 trial investigating Keytruda, Merck's anti-PD-1 therapy, in combination with standard of care chemotherapy then continued as a single agent every six weeks for up to 14 cycles for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient, or pMMR, or mismatch repair deficient, or dMMR. Results from the trial showed the Keytruda regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, for patients, regardless of mismatch repair status. These late-breaking data are being presented for the first time during a scientific plenary at the 2023 Society of Gynecologic Oncology, or SGO, Annual Meeting on Women's Cancer and are also being simultaneously published in the New England Journal of Medicine. The results are being discussed with regulatory authorities worldwide. In the pMMR cohort of 591 evaluable patients, after a median follow-up of 7.9 months, the Keytruda regimen significantly reduced the risk of disease progression or death by 46% compared to chemotherapy alone; median PFS was 13.1 months for the Keytruda regimen versus 8.7 months for chemotherapy alone. In the dMMR cohort of 225 evaluable patients, after a median follow-up of 12 months, the Keytruda regimen significantly reduced the risk of disease progression or death by 70% compared to chemotherapy alone; median PFS was not reached for the Keytruda regimen versus 7.6 months for chemotherapy alone. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified. Grade 3-5 adverse events, or AEs, occurred in 55.1% of patients receiving the Keytruda regimen and 45.3% of patients receiving chemotherapy alone in the pMMR cohort. In the dMMR cohort, Grade 3-5 AEs occurred in 63.3% of patients receiving the Keytruda regimen and 47.2% of patients receiving chemotherapy alone. There were no Keytruda -related AEs leading to death in either cohort.

17:06 EDT Transcat acquires TIC-MS for $9.7M in cash and stock deal - Transcat announced that it has purchased all of the capital stock of privately-held TIC-MS, Inc., effective March 27, 2023. The purchase price of $9.7M was paid in combination of 70% stock and 30% cash and is subject to certain customary holdback provisions. Founded in 1986, TIC-MS is an ISO/IEC 17025 accredited calibration laboratory with an extensive scope specializing in physical dimensional and electronics capabilities. TIC-MS services a diverse customer base with accredited calibrations performed at both the customer's location and at their recently built calibration laboratory located in St. Louis, Missouri. Existing leadership and staff will remain onboard and continue to service customer needs. "With over thirty-five years in the industry, TIC-MS is a well-established, quality-focused business with strong leadership. This acquisition strengthens our presence in this marketplace, complementing nicely with the capabilities and customers served by our existing Transcat St. Louis Lab," commented Lee Rudow, President and Chief Executive Officer. "Additionally, our future plans include co-locating the two operations, leveraging the infrastructure synergies of one lab location and drive efficiencies. This combination will more than double our existing presence in the region."

17:01 EDT Perma-Pipe International takes steps to expand to Qatar - Perma-Pipe International has taken preliminary steps to expand operations to Qatar and mobilization is expected to commence during the current year. In addition to the local district heating and cooling market, there are numerous significant future developments in the oil and gas industry which the company will position itself for.

16:55 EDT Monopar Therapeutics Inc trading halted, news pending

16:50 EDT Enviva announces John Keppler to return as chairman - Enviva announced that John Keppler is returning to the company as executive chairman, effective April 1. Thomas Meth will continue to lead the company as president and CEO, and the company's interim chairman, Ralph Alexander, will transition to the role of lead independent director of the board. As previously announced, Keppler stepped down from his role as chairman and CEO of Enviva to address a heart condition. With Keppler's recovery and rehabilitation following heart surgery well underway, he is returning to the company to support his co-founding partner and CEO, Thomas Meth. As executive chairman, in cooperation with Meth, Keppler is expected to help drive strategic corporate initiatives, growth, and interaction with key capital markets and financial stakeholders.

16:36 EDT Sigmatron International receives noncompliance notification from Nasdaq - SigmaTron International received a delinquency notification letter from Nasdaq indicating that the company is not in compliance with the continued listing requirements under Nasdaq Listing Rule 5250 because the company did not timely file its Form 10-Q for the fiscal quarter ended January 31. The notification letter has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market.

16:31 EDT Forum Energy awarded roughly $25M contract to provide desalter systems - Forum Energy Technologies has been awarded an approximately $25M contract to design, engineer, and supply four electrostatic desalter systems for an onshore project at the Safaniyah oil field, Kingdom of Saudi Arabia. The desalter systems will utilize FET's EDGE desalting technology, ForuMix high efficiency multiphase mixer technology, as well as in-house manufacturing capabilities at FET's facility in Dammam, Saudi Arabia. Neal Lux, President and Chief Executive Officer, remarked, "This award demonstrates the value FET provides through its extensive technology portfolio and global reach. Building on our technologies' successful track record, we are pleased to be working with Saudi Aramco on another important project."

16:30 EDT Applied Molecular Transport trading resumes

16:27 EDT AAR Corp. announces distribution agreement with Cloud Cap Technology - AAR Corp. announced a distribution agreement with Cloud Cap Technology, a Collins Aerospace Mission Systems business. This agreement expands AAR's presence in the Unmanned Aerial System, or UAS, market, building on AAR's civil and government relationships as well as its proven supply chain and sales support processes. AAR will stock, promote, and sell the TASE and Piccolo imaging payload and flight management systems used by manned and unmanned airborne applications to support Intelligence, Surveillance, and Reconnaissance, or ISR, missions. Customers are expected to include UAS manufacturers, airframers, as well as civil and government operators.

16:26 EDT Invesco Mortgage says no direct counterparty exposure to Credit Suisse - Invesco Mortgage (IVR) said it has no direct counterparty exposure to Credit Suisse (CS). As of March 17, the company had total investment portfolio of $5.5B, unrestricted cash and unencumbered investments totaling approximately $454M, 90% of $4.9B repurchase agreement borrowings hedged with a net $4.4 billion notional of pay fixed/receive floating interest rate swaps, debt-to-equity ratio estimated to be 5.9 times, and economic debt-to-equity ratio estimated to be 5.9 times.

16:24 EDT Invesco Mortgage cuts quarterly dividend to 40c from 65c - Invesco Mortgage Capital announced that its board declared a cash dividend of 40c per share of common stock for Q1, down from 65c. The dividend will be paid on April 27, to stockholders of record on April 10, with an ex-dividend date of April 6. "Our investment portfolio continues to generate strong earnings available for distribution despite the sharp increase in short-term interest rates given a high percentage of our funding is hedged with a relatively low-cost legacy swap portfolio. We reduced our common stock dividend to retain capital and enhance book value by continuing to invest in agency residential mortgage-backed securities at historically attractive valuations. We believe this represents a compelling environment for longer-term investors. The dividend reduction allows us to pay a competitive dividend consistent with Agency RMBS market levered returns and helps increase the ratio of our common stock to total stockholders' equity," said John Anzalone, Chief Executive Officer.

16:11 EDT MaxCyte appoints Douglas Swirsky as CFO - MaxCyte announced Douglas Swirsky has been appointed as the company's CFO, effective immediately. Swirsky is a financial executive with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. Prior to joining MaxCyte, Mr. Swirsky served as CFO and treasurer of AavantiBio.

16:07 EDT WM Argyle Fund issues statement regarding Broadwind director appointment - WM Argyle Fund, which has nominated three director candidates to the Broadwind board of directors in connection with the 2023 annual meeting of stockholders, issued the following statement: "The Fund views this appointment - which increases the board to seven members - as an attempt by Broadwind to blunt criticism of the Company, protect the current Board and block meaningful change. This appointment marks the second time the Company has named a new director since the Fund first contacted the Board in July 2022 to open a constructive dialogue about its governance and performance. The Board's actions show it is not ready do what is required to position the Company for long-term success to benefit stockholders, who have endured years of underperformance by the Company."

16:04 EDT Energy Transfer to acquire Lotus Midstream for roughly $1.45B - Lotus Midstream and its financial sponsor EnCap Flatrock Midstream announced they have signed a definitive agreement to sell Lotus Midstream to Energy Transfer LP for approximately $1.45B. The transaction is expected to close in the second quarter of 2023, subject to regulatory approval and customary closing conditions. "We are thankful for the opportunity provided by EnCap Flatrock to have grown and developed Centurion Pipeline," said Lotus Midstream CEO Mike Prince. "We have had the good fortune to work alongside outstanding and dedicated people, who are responsible for Centurion's collective success." "We are pleased to have reached agreement with Energy Transfer for the sale of Lotus Midstream," said EnCap Flatrock Managing Partner Greg King. "Mike, Emily, Jen and the Lotus team built a fantastic business. We are grateful for their partnership and are thankful to our investors for their support of this significant investment for EnCap Flatrock." Jefferies served as financial advisor and Vinson & Elkins as legal advisor to Lotus Midstream, and Sherman & Sterling as EnCap Flatrock's legal advisor.

16:00 EDT Applied Molecular Transport trading halted, news pending

15:05 EDT L3Harris Technologies announces CRADA with Army for ground combat vehicles - L3Harris Technologies announced a Cooperative Research and Development Agreement, or CRADA, with the U.S. Army's Combat Capabilities Development Command, or DEVCOM, Ground Vehicle Systems Center, or GVSC, to collaborate on the implementation of the Army's Modular Open Systems Approach, or MOSA, for its ground combat vehicles. The Department of Defense's MOSA strategy aims to shorten development timelines, reduce costs, and ensure warfighters are mission ready across land, air and sea. As an industry collaborator, L3Harris will advise on an open-systems direction.

14:35 EDT JATT Acquisition Corp trading halted, volatility trading pause

13:57 EDT FDIC investigating misconduct in management of SVB Financial, Signature Bank - The FDIC released prepared remarks by Chairman Martin Gruenberg on "Recent Bank Failures and the Federal Regulatory Response before the Committee on Banking, Housing, and Urban Affairs" that will be presented to the United States Senate, in which Gruenberg states in part: "After careful analysis and deliberation, the Boards of the FDIC and the Federal Reserve voted unanimously to recommend, and the Treasury Secretary, in consultation with the President, determined that the FDIC could use emergency systemic risk authorities under the Federal Deposit Insurance Act to fully protect all depositors in winding down SVB and Signature Bank. It is worth noting that these two institutions were allowed to fail. Shareholders lost their investment. Unsecured creditors took losses. The boards and the most senior executives were removed. The FDIC has authority to investigate and hold accountable the directors, officers, professional service providers and other institution-affiliated parties of the banks for the losses they caused to the banks and for their misconduct in the management of the banks. The FDIC has already commenced these investigations. Further, any losses to the FDIC's Deposit Insurance Fund as a result of uninsured deposit insurance coverage will be repaid by a special assessment on banks as required by law." Reference Link

13:17 EDT Air Products announces supply contracts from NASA totaling more than $130M - Air Products announced it recently was awarded several supply contracts from NASA totaling more than $130M to provide liquid hydrogen for several NASA locations including the Kennedy Space Center, Cape Canaveral Space Force Station, and other NASA facilities. "Under one public contract, Air Products will supply NASA liquid hydrogen to support operations at the Kennedy Space Center and nearby Cape Canaveral Space Force Station. The multi-year contract, which is already in effect, includes a maximum value of approximately $75M. NASA also awarded Air Products a separate public contract, valued at a maximum value of over $57M to supply liquid hydrogen to facilities across the agency including NASA's Marshall Space Flight Center in Huntsville, Alabama, and the Stennis Space Center in Bay St. Louis, Mississippi. NASA uses liquid hydrogen, combined with liquid oxygen, as fuel in cryogenic rocket engines, and hydrogen's unique properties support the development of aeronautics," the company stated.

13:02 EDT CN, Trealmont, Kaptan plan for new Calgary intermodal transload facility - CN, Trealmont Transport Inc. and Kaptan US LLC announced they have reached an agreement to develop a multimodal transload facility located in CN's Calgary Logistics Park. The new facility is planned to be operational in the third quarter of 2024. Kaptan and Trealmont Transport have agreed to purchase land located within CN's Calgary Logistics Park and will build a logistics facility designed for transloading intermodal containers originating and departing from the ports of Prince Rupert and Vancouver.

12:57 EDT Incyte granted orphan status for myelofibrosis treatment - The FDA granted Incyte orphan status for parsaclisib and ruxolitinib, its treatment of myelofibrosis. Reference Link

12:43 EDT Kludein I Acquisition Corp trading resumes

12:00 EDT Autodesk names Sebastian Goodwin chief trust officer - Autodesk announced the appointment of Sebastian Goodwin as chief trust officer, starting March 27, 2023. As chief trust officer, Goodwin will oversee the fulfillment of Autodesk's commitments to its customers and stakeholders on security, privacy, and data ethics. "Trust is essential to our relationships with customers and partners, and it's a responsibility we share across Autodesk," said Raji Arasu, executive vice president and chief technology officer. "With Sebastian's expertise in developing and implementing effective security strategies, managing complex risk scenarios, and fostering a culture of trust, he is the ideal steward to guide and deliver Autodesk products and industry clouds on a trusted platform. I'm thrilled to welcome him to the team." Goodwin joins Autodesk from his previous role as chief information security officer at Nutanix.

12:00 EDT OneConnect falls -6.8% - OneConnect is down -6.8%, or -40c to $5.42.

12:00 EDT Novartis rises 7.5% - Novartis is up 7.5%, or $6.24 to $89.83.

12:00 EDT First Republic rises 15.5% - First Republic is up 15.5%, or $1.92 to $14.28.

11:14 EDT Labcorp pays $2.1M to resolve False Claims Act allegations - Laboratory Corporation of America has agreed to pay the United States $2.1M to resolve allegations that it violated the federal False Claims Act by overbilling the Department of Defense for genetic tests performed by GeneDx, a third-party reference laboratory used by Labcorp to perform genetic tests for military members. The civil settlement resolves a lawsuit filed by Donna Hecker-Gross, a former employee of Labcorp, under the whistleblower provision of the False Claims Act, the Justice Department said in a statement. Reference Link

11:04 EDT Lucid recalls 2022-2023 Lucid Air vehicles for issue with electric motors - Lucid Group (LCID) is recalling certain 2022-2023 Air vehicles, stating in a filing dated March 23 with the NHTSA that electrically activated contact switches that transfer energy to the drive motors may unexpectedly open, cutting off power to the electric motors. "This may lead to a loss of propulsion without pre-warning and may increase the risk of a crash," the company said in the filing. The potential number of units affected is 637 vehicles, according to the NHTSA filing. Sensata Technologies (ST) is the supplier that manufactures the contactors for 2022 and 2023 Lucid Air vehicles, the filings with the regulator stated. Reference Link

10:35 EDT Dine Brands intends to refinance certain senior secured notes - Earlier, Dine Brands announced its intention to refinance its Series 2019-1 Class A-2-I, Fixed Rate Senior Secured Notes, stating that the Series 2019-1 Class A-2-II, Fixed Rate Senior Secured Notes and the Series 2022-1 Class A-1, Variable Funding Senior Notes are not proposed to be refinanced as this time. As of March 24, the principal balance of the Series 2019-1 Refinancing Notes was approximately $585M. Dine Brands intends to replace the 2019-1 Refinancing Notes with a new securitized financing facility, expected to be comprised of between $400M-$500M of Senior Term Notes. The net proceeds of the sale of the new notes, and the use of cash on hand and Variable Funding Senior Notes, would be used to repay any outstanding amounts under the 2019-1 Refinancing Notes in full, to pay fees and expenses incurred in connection with the issuance of the new botes and to the extent any net proceeds remain, for general corporate purposes. "There can be no assurance regarding the timing of a refinancing transaction, the interest rate at which the 2019-1 Refinancing Notes would be refinanced, or that a refinancing transaction will be completed," the company stated.

10:04 EDT ENC receives order for three Axess EVO-FC buses - ElDorado National secured an order for three Axess EVO-FC zero emissions hydrogen fuel cell buses from Rochester-Genesee Regional Transportation Authority. The Axess EVO-FC buses, which only have water as a byproduct, will help RGRTA as it works toward a goal of transitioning to a zero-emissions fleet by 2035. The transportation provider received funding for its Axess EVO-FC buses through the Federal Transit Administration Low- and No-Emission program.

10:02 EDT WPP announces acquisition of social influencer marketing agency Obviously - WPP announced the acquisition of Obviously, a technology-led social influencer marketing agency based in New York, with operations in San Francisco and Paris. "Obviously offers a full stack of end-to-end services, including marketing strategy, influencer identification, content creation, campaign management, and robust reporting and analysis. Its team of nearly 100 people will join VMLY&R's network, accelerating the WPP agency's investment in award-winning data and social media work. Obviously's tech offerings include automating processes; streamlined workflow between influencers, clients and internal teams; and enhancing data to deliver real-time campaign and audience insights. The agency's unique data analytics infrastructure also leverages AI to deliver predictive analysis and assess campaign pricing and benchmarking," WPP stated.

10:01 EDT Trinseo says latex emulsion release to waterway caused by equipment failure - Trinseo provides the following update regarding the accidental release of an estimated 8,100 gallons of latex emulsion product from the Altuglas LLC manufacturing facility in Bristol, Pennsylvania. The release was the result of an equipment failure. Some of the material overflowed the on-site containment system and entered a storm drain, where it flowed to Otter Creek and then to the Delaware River. Trinseo personnel alerted federal, state, and local authorities and immediately began to participate in the emergency response. Because the material is highly water soluble, and the release coincided with a period of rainfall, the material dissipated quickly in the water. To assess potential impacts, water samples were collected at designated locations. Results received to date have not detected the released material. Trinseo is continuing to work cooperatively with the U.S. Coast Guard, U.S. EPA, Pennsylvania Department of Environmental Protection, and local authorities to assess potential impacts and any remedial measures to address the release. Trinseo voluntarily paused all production operations at the facility to devote its full resources to addressing the release and to conduct a thorough review and analysis of all material-handling processes and equipment at the Bristol facility. Trinseo will make improvements as necessary to achieve a standard of environmental excellence that its employees, investors and community expect and that, to date, has been a hallmark of Trinseo's business performance. Following an internal review of operations, Trinseo expects to resume partial production within the next several days, and to resume full production shortly thereafter. Trinseo is working to minimize any potential customer impacts. The Bristol facility manufactures acrylic resins for Trinseo's Engineered Materials business. The plant employs approximately 110 people.

10:00 EDT Direxion Financial Bear 3x falls -5.1% - Direxion Financial Bear 3x is down -5.1%, or -$1.26 to $23.28.

10:00 EDT KeyCorp rises 7.9% - KeyCorp is up 7.9%, or 94c to $12.79.

10:00 EDT First Republic rises 22.8% - First Republic is up 22.8%, or $2.82 to $15.18.

09:50 EDT Jounce Therapeutics trading resumes

09:47 EDT OneConnect falls -5.2% - OneConnect is down -5.2%, or -30c to $5.51.

09:47 EDT Direxion Financial Bear 3x falls -5.5% - Direxion Financial Bear 3x is down -5.5%, or -$1.35 to $23.19.

09:47 EDT KeyCorp rises 8.2% - KeyCorp is up 8.2%, or 97c to $12.83.

09:39 EDT Alpine Acquisition Corp trading halted, volatility trading pause

09:31 EDT PRA Group names Vikram Atal as CEO, succeeding Kevin Stevenson - PRA Group announced that its board of directors has elected longtime board member Vikram Atal as its president and CEO, effective immediately. Atal replaces Kevin Stevenson, who has served as president and CEO since 2017 and is leaving the company. Atal joined PRA Group's board in 2015 and served on the audit committee and as chair of the risk committee.

09:23 EDT Cann American Corp. completes acquisition of Prodigy Stem Cell - Cann American Corp. announced a shareholder update for 2023. On March 1, 2023, the Company completed the acquisition of Prodigy Stem Cell. With this acquisition the Company intends to expand its overall direction as a holding company engaged in alternative therapeutics ranging from CBD to regenerative medicines. The Company will be, in the near term, focused primarily on expanding the Prodigy brand and vision originally launched under Prodigy's founder and recently appointed CNNA director, Pete Caruso. Based on publicly available research reports, the global stem cell market is currently valued at approximately $12 billion with projections to reach approximately $30 billion by 2030. Prodigy expects its business model to capture significant US market share over the next several years. With exclusive laboratory access to the highest quality stem cells in the market, Prodigy is initiating a multi-prong business plan. As a wholesaler Prodigy will be offering its product lines to Dr.'s, sports medicine facilities, plastic surgery centers, and similar health and wellness clinics nationwide. This will be achieved through an extensive marketing campaign including conventions and brand ambassadorships. Prodigy has already began to recruit high profile athletes, who are also current clients, to promote the Prodigy brand. Secondly, Prodigy intends to rapidly expand into several of its own Prodigy branded wellness centers at strategic locations throughout the US. The Company is currently planning to launch a new facility in Florida, in addition to its flagship New Jersey office, within the coming weeks. Prodigy locations will be strategically opened in regions that host major sporting facilities and professional athletic training camps as its target market. As the Company aggressively embarks on advancing Prodigy Stem Cell, it is also nearing conclusion of its financial audits to up-list from alternative reporting to SEC reporting. With the belief that Prodigy is a world class product, the Company is committed to representing its portfolio on at least the OTCQB tier as soon as possible.

09:22 EDT NeuroSense signs collaboration agreement with MA General Hospital - NeuroSense Therapeutics announced it has signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital's NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue. The objective of the collaborative studies is to expand the understanding of PrimeC's mechanism of action in attenuating ALS-related pathology, specifically TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress. To address this, ALS- or control-SNs derived from post-mortem brains will be used to treat SH-SY5Y cells to induce reactive oxygen species and mitochondrial dysfunction, as previously shown by the Sadri-Vakili lab, in the presence or absence of PrimeC. Importantly, the studies will compare the potential therapeutic effect of PrimeC combination therapy relative to each one of its FDA-approved compounds, ciprofloxacin and celecoxib, separately, to further demonstrate the beneficial synergistic effect of PrimeC as a combination therapy.

09:16 EDT Crown Electrokinetics enters agreement with infrastructure solutions provider - Crown Electrokinetics has entered into an agreement with a infrastructure solutions provider. Crown Fiber Optics new customer is a provider of engineering, construction, program and project management to the telecommunications and utility industries. Doug Croxall, Crown Electrokinetics CEO and Chairman stated, "We are excited to announce the acquisition of our third customer, the second in as many months. We estimate that this multi-phased project may generate up to $30 million of revenue for Crown. We are continuing to expand not only within our existing customers' footprint, but also by adding more customers in the near future."

09:12 EDT Oncternal Therapeutics reports inducement award under Nasdaq listing rule - Oncternal Therapeutics announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT. The award will be made on April 3, 2023 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 64,900 shares of Oncternal common stock. The option will have a 10-year term and an exercise price equal to the closing price of Oncternal's common stock on the date of grant. The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the employee's start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal's compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and will be granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).

09:11 EDT Scilex reports substantial underreporting of over 44M shares of common stock - Scilex Holding announced that there are more than 44 million shares of its common stock that have not yet been reported by brokers, banks and other nominees to Broadridge Financial Solutions an independent third party that collects and tabulates stockholder votes for the upcoming annual meeting of Scilex's stockholders, to be held on April 6, 2023. On March 9, 2023, Broadridge distributed the proxy materials for the Annual Meeting to all Scilex stockholders of record as of March 6, 2023, the record date for the Annual Meeting. The widespread and substantial non-reporting and under-reporting of eligible stockholder votes poses a serious risk of legal challenge as Delaware law and Scilex's bylaws provide that each stockholder is entitled to one vote for each share of Scilex capital stock held by such stockholder on all matters on which stockholders generally are entitled to vote. Under Federal law, specifically Rule 14b-1 of the Securities Exchange Act of 1934, brokerage firms are required to forward the Annual Meeting proxy materials received from Scilex to such brokerage firms' customers who are the beneficial owners of Scilex capital stock no later than five business days after receipt of such materials. Rules of the Financial Industry Regulatory Authority also require brokerage firms to distribute proxy materials to such brokerage firms' customers. These rules are designed to ensure that stockholders are informed of their right to vote at the Annual Meeting. Given that more than 44 million shares of Scilex common stock have not yet been reported by brokerage firms to Broadridge, Scilex believes that certain brokerage firms have not complied with, and thus violated, their legal obligation to deliver the Proxy Materials to their customers and inform such customers of their right to vote at the Annual Meeting. As a result, such brokerage firms may be subject to sanctions and investigation by US government regulatory agencies as well as legal action by Scilex stockholders. To protect the voting rights of Scilex stockholders , Scilex is reporting to, and coordinating with, regulatory agencies, including FINRA, to investigate the widespread and substantial non-reporting and under-reporting of eligible stockholders' votes and may bring appropriate legal action in due course. Scilex, together with Sorrento, previously provided a series of "Frequently Asked Questions" documents under the "Investors" section of Sorrento's website at www.sorrentotherapeutics.com regarding Sorrento's distribution of the Dividend Stock to its stockholders and is today providing a further update to the FAQs to clarify the voting rights of Scilex stockholders at the Annual Meeting on April 6, 2023 and to request that all Scilex stockholders contact their respective brokerage firms to demand delivery of the Proxy Materials for the Annual Meeting (and any additional proxy soliciting materials Scilex distributes to such firms from time to time) and instructions on how to vote their shares of Scilex common stock at the Annual Meeting.

09:08 EDT American International Holdings completes acquisition of Cycle Energy Corp. - American International announces that it has entered into a Share Exchange Agreement with Cycle Energy Corp. and Marble Trital, the sole shareholder of Cycle Energy whereby the Shareholder exchanged 100% of the ownership of Cycle Energy in consideration for 1,000,000 shares of the Series A Preferred Stock of the Company. Pursuant to the Exchange Agreement, which closed on February 15, 2023, Cycle Energy is now a wholly-owned subsidiary of AMIH. "The acquisition of Cycle Energy Corp. is the next fundamental step in our evolution as a company," stated Michael McLaren, CEO of American International Holdings Corp., who continued, "With our business strategy of 'Acquire, Restore, Produce' using our state-of-the-art equipment and technologies, we believe being a fully reporting issuer traded on the OTCQB markets will allow us to grow at a faster pace than ever before."

09:07 EDT LPL Financial: SC Financial Group joins broker-dealer, RIA, custodial platforms - LPL Financial announced that SC Financial Group has joined LPL Financial's broker-dealer, RIA and custodial platforms. The team reported having served approximately $220 million in advisory, brokerage and retirement plan assets, and joins LPL from Cadaret Grant & Co, now part of the Atria Group. Financial advisors Shane Cloninger and Susan Carter, who has since retired, founded the Bellevue, Wash.,- based practice in 2008 with a mission to deeply understand and foster each client's true needs and financial goals. The multigenerational practice has evolved over the years to include fellow advisors Robert Davis, Rumesh Senanayake and Alex Carter, Susan's son.

09:06 EDT First Citizens: Capital ratios remains robust after SVB pact - Comments taken from investor conference call.

09:05 EDT Cal-Maine Foods names Todd Walters COO - Cal-Maine Foods announced that Todd Walters has been named COO and Matt Whiteman has been named VP, Operations, both effective March 27. Walters joined Cal-Maine Foods in 1997. Since 2011, he has served as VP of operations for the company's operations in South Texas, as well as our subsidiary Wharton County Foods, LLC's facility in Boling, Texas.

09:04 EDT Silo Pharma announces filing of patent for treatment of fibromyalgia - Silo Pharma announced that it has filed a provisional patent application titled "Methods and Compositions for Pain Management." The methods and compositions described in the patent application can be used in ameliorating pain, including chronic pain such as fibromyalgia, which occurs in approximately 2% of the United States general population. Fibromyalgia is the initially targeted indication for the Company's drug, SP-26. "This provisional patent application supports our multi-pronged strategy for advancing SP-26 into the clinic. The Company is working towards submitting an IND package to the FDA and pursuing the 505(b)(2) regulatory pathway for SP-26. We believe our drug would serve a critical need in a largely inadequate treatment landscape for chronic pain including fibromyalgia," said Eric Weisblum, Chief Executive Officer of the Company.

09:03 EDT Jounce to be acquired by Concentra for $1.85 in cash per share plus CVR - Jounce Therapeutics entered into a definitive merger agreement whereby Concentra Biosciences will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right. The $1.85 per share upfront consideration represents a premium of approximately 75% to Jounce's closing share price immediately prior to the March 14, 2023 public disclosure of Concentra's acquisition proposal. Following a thorough review process conducted with the assistance of its legal and financial advisors, Jounce's Board of Directors has determined that the acquisition by Concentra - of which Tang Capital Partners, LP is the controlling shareholder - is in the best interests of all Jounce shareholders, and has unanimously approved the merger agreement. Jounce's Board of Directors is no longer recommending the proposed all-share merger transaction. The Jounce Board of Directors has notified Redx of the withdrawal of its recommendation in favor of the Redx Business Combination and termination of the co-operation agreement dated February 23, 2023 between Jounce and Redx. In conjunction with the merger agreement, Jounce is implementing a workforce reduction of approximately 84% of its employees. This reduction is expected to be completed within the next month and Jounce will incur restructuring costs totaling approximately $6.5 million1. The remaining Jounce employees will work to complete the sale of the Company, conduct activities to maximize the value of the CVR, work to ensure that patients on the SELECT and INNATE trials have the opportunity to continue receiving therapy with vopratelimab, JTX-8064 and pimivalimab and to otherwise ensure a smooth transition to Concentra. Pursuant and subject to the terms of the merger agreement, a subsidiary of Concentra will commence a tender offer by April 7, 2023 to acquire all outstanding shares of Jounce for $1.85 in cash per share at closing plus a non-tradeable CVR representing the right to receive 80% of the net proceeds payable for a period of ten years post-closing from any license or disposition of Jounce's programs effected within two years of closing and 100% of the potential aggregate value of certain specified potential cost savings.Closing of the tender offer is subject to certain conditions, including the tender of Jounce shares representing at least a majority of the total number of outstanding shares as of immediately following the consummation of the offer; the availability of at least $110 million of cash and cash equivalents, net of any tail and closing costs, at closing, and other customary conditions. The acquisition is expected to close in the second quarter of 2023.

09:02 EDT Philips announces debut of Philips Virtual Care Management - Royal Philips announced the debut of Philips Virtual Care Management, a comprehensive portfolio of flexible solutions and services to help health systems, providers, payers and employer groups more meaningfully motivate and deeply connect with patients from virtually anywhere. Philips Virtual Care Management can help reduce pressure on hospital staff by decreasing emergency department visits, as well as reducing the cost of care through better management of chronic disease. "Virtual care is paving the way to meaningfully reduce the cost of care through fewer hospitalizations and emergency department visits," said Nick Wilson, General Manager, Ambulatory Virtual Care at Philips. "Care providers and health systems today are often short on time and resources, accelerating the need to find new ways to gain visibility into patients' health amid an overwhelming variety of options. For patients, the opportunity to understand and take proactive control of their health can potentially lead to improved outcomes."

08:58 EDT Anika Therapeutics files preliminary proxy statement - Anika Therapeutics announced that it has filed its preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming 2023 Annual Meeting of Stockholders. The meeting date has not yet been scheduled and shareholders do not need to take any action at this time. In its preliminary proxy statement, the Anika Board of Directors recommends that shareholders vote for the re-election of its two nominees - John Henneman, III and Susan Vogt - at the Annual Meeting. Mr. Henneman and Ms. Vogt joined the Board as part of the Company's active Board refreshment process, through which five new independent directors have been appointed since 2018, three of whom were appointed in the last three years. With the re-election of Mr. Henneman and Ms. Vogt, Anika's purpose-built Board will comprise seven highly qualified individuals, all of whom bring expertise in areas relevant to the Company's business, including orthopedics, medical devices and pharmaceuticals expertise, R&D, innovation and commercial experience and manufacturing and financial oversight. The Company also disclosed that a shareholder, Caligan Partners, has submitted two candidates for election to the Board of Directors. Over the last eight months, members of Anika's Board and management team have engaged extensively with Caligan. Caligan has made clear its view that the Company should exit the Joint Preservation and Restoration business and return capital to shareholders while also launching a strategic review process to sell the entire Company. The Anika Board believes that electing either of Caligan's candidates would jeopardize the value of its shareholders' investment in the Company. The Anika Board of Directors will maintain its unwavering commitment to acting in the best interests of all of the Company's shareholders.

08:48 EDT Wix.com announces expanded integration with Meta Platforms - Wix.com Ltd. announced expanded integrations with WhatsApp, Instagram and Messenger where Wix users can now connect their business accounts directly with their Wix Inbox. By integrating these channels, business owners can more efficiently manage all communication and interactions with their customers from one inbox in one place.

08:43 EDT Biofrontera Inc. announces investment in dermatology salesforce - Biofrontera is executing on the company's stated plans to invest in and meaningfully grow its' salesforce in 2023. "With this investment in the salesforce, Biofrontera is taking an important step forward in our growth strategy," stated Erica Monaco, CEO. "The success of our FDA-approved therapy for actinic keratosis, Ameluz-PDT, is directly related to our ability to educate dermatologists and patients about AK and the potential health benefits of our therapy. The strengthening of our sales effort will greatly improve our reach in key dermatology markets across the United States and position us well to further penetrate this large opportunity. We achieved record revenues and grew market share in 2022 with fewer sales people and territories than we had pre-COVID - an example of the capabilities of our current team. Today, we are adding a new sales region and growing the salesforce by almost 30% to now cover 40 territories. We are also adding a combined 140 years of healthcare and dermatology experience to our existing customer coverage. Biofrontera is at an important, business inflection point and we are confident that this expansion of the salesforce will enable us to accelerate growth and continue our market share gains in 2023 and beyond."

08:41 EDT Davids Tea trading halted, news pending

08:40 EDT NLS Pharmaceutics announces OLE study six-month data for Quilience - NLS Pharmaceutics announced the final results from its Open Label Extension Study for Quilience in the treatment of narcolepsy. The OLE study offered patients completing the 4-week randomized, double blind Phase 2 trial for Mazindol ER the option to receive the drug candidate, Mazindol ER, for an additional 6 months as a once-daily, monotherapy on an open-label basis. Of the 60 patients who completed the randomized controlled DB Phase 2 trial, 87% of patients elected to enroll into the OLE study. The most frequent adverse events reported were dry mouth, COVID-19, constipation, urinary tract infection and nausea, and there were no serious adverse events related to study medication. This 6-month OLE study of Mazindol ER, a first in class, unique dual mechanism of action pan-monoamine reuptake inhibitor and orexin-2 partial receptor agonist, showed that patients treated with Mazindol ER in the randomized Phase 2 trial saw an additional improvement of 0.8 points in excessive daytime sleepiness on the Epworth Sleepiness Scale. At the conclusion of the OLE, the mean ESS score for these patients reached 8.9, with lower scores denoting an improvement in the condition. Of note, ESS scores of 10 or below are considered typical scores for subjects without narcolepsy. As previously concluded in the interim analysis of the OLE reported in September 2022, these data indicate that maximum efficacy on ESS with Mazindol ER is reached at approximately 2 months of treatment, and these scores were subsequently maintained throughout the 6-month OLE duration. Overall, the mean ESS score for these patients declined by approximately 10.2 points from their DB study baseline to month 6 in the OLE. Similarly, patients receiving placebo in the DB Phase 2 trial who rolled over to receive Mazindol ER in the OLE study, saw an improvement in ESS scores, declining to levels comparable to those treated with Mazindol ER in both the DB and OLE trials. This effect was maintained through the 6-month OLE study, with ESS scores similar to the DB Mazindol ER group. Patients with Narcolepsy Type 1 treated with Mazindol ER in the randomized Phase 2 trial, experienced a mean number of weekly cataplexy episodes of approximately 2.9 at the end of the 4-week DB period, down from a baseline level of approximately 16.6 at the beginning of the trial. During the 6-month OLE study, mean weekly cataplexy episodes for these patients remained relatively stable in the 2 to 4 range through week 24. For NT1 patients with cataplexy receiving placebo in the DB Phase 2 trial, the mean number of weekly cataplexy episodes was approximately 10.3 at the end of the 4-week double-blind period. During the 6-month OLE study, when treated with Mazindol ER, these patients caught up to previously treated patients, achieving mean weekly cataplexy episodes of 3.8 at 8 weeks of treatment. This favorable effect was maintained for these patients in the 2-4 episodes per week range throughout the 6-month OLE study. For both groups, the mean reduction in weekly cataplexy episodes was more than 80% from the DB study baseline. Notably, there were patients diagnosed with Narcolepsy Type 1 who achieved zero weekly cataplexy episodes in the OLE study, with some of those maintaining this effect through week 24. For example, the graphs below show the results of a 23 year-old female with NT1 who received Mazindol ER in both the DB and OLE study periods. This study showed favorable subject participation and retention, especially given the broad exclusion of all narcolepsy, depression, and anxiolytic medications, as well as other medications such as oral contraceptives. There were no treatment-related serious adverse events. The most frequent adverse events were dry mouth, COVID-19, constipation, urinary tract infection and nausea. The results confirmed that Mazindol was safe and well tolerated, with no unexpected adverse events throughout the combined studies.

08:39 EDT BioSig Technologies announces new advisory board member Edwin Wang - BioSig Technologies announced the appointment of new Advisory Board member Edwin Wang. Wang has over 20 years of experience in private equity, venture capital, merchant banking, and family office investing. He is the founder of Accretive Capital Partners.

08:36 EDT Kore Group to acquire Twilio's IoT business unit - Kore Group (KORE) announced the signing of a definitive agreement to acquire Twilio's (TWLO) IoT business unit as part of a growth strategy to provide customers with a unified, seamless approach to launching IoT solutions as the world's leading pure-play IoT provider. As consideration for the acquisition, Twilio will receive 10M shares of Kore common stock, which will represent approximately 11.5% of Kore's issued and outstanding shares. Completion of the acquisition transaction is subject to customary closing conditions, including, among other things, the negotiation and execution of certain ancillary agreements.

08:35 EDT NanoXplore announces purchase of Martinrea's stake in VoltaXplore - NanoXplore (NNXPF) and Martinrea International (MRETF) through its subsidiary, Martinrea Innovation Developments announced NanoXplore's purchase of Martinrea Innovation's 50% equity stake in VoltaXplore for an aggregate equity consideration of $10 million on March 24, 2023. NanoXplore now owns 100% of the equity and intellectual property in VoltaXplore and Martinrea has increased its existing equity position in NanoXplore from 21.1% to 22.7%. VoltaXplore was formed as a joint venture between NanoXplore and Martinrea in 2021 to collaborate on developing graphene-enhanced Li-ion battery cells for electric vehicles and grid storage and to explore the potential to build a battery gigafactory. NanoXplore will seek to finance the battery gigafactory within VoltaXplore, without dilution to NanoXplore's shareholders. The purchase transaction simplifies VoltaXplore's capital structure to enhance the access to government and private fundings. Moreover, concurrent to this transaction, NanoXplore and Martinrea agreed to extend their existing graphene commercial agreement by another 5 years to 10 years which reinforces the strong relationship between the two companies. To acquire the remaining equity ownership in the joint venture, the Corporation issued 3,420,406 common shares to Martinrea priced at $2.92 per NanoXplore's share. NanoXplore's share price is calculated based on the volume-weighted average trading price of the common shares of NanoXplore on the Toronto Stock Exchange for the twenty trading days prior to closing. Following the completion of the transaction, Martinrea and its affiliates hold 38,466,360 common shares of NanoXplore representing approximately 22.7% of the issued and outstanding common shares of the Corporation.

08:34 EDT Blackbaud board rejects proposal from Clearlake Capital - Blackbaud confirmed that its board of directors received, thoroughly reviewed and rejected an unsolicited, non-binding proposal from Clearlake Capital Group, L.P. to acquire all of the outstanding shares of the company for $71.00 per share in cash. The Board is open to and regularly evaluates opportunities to enhance value, and the Clearlake proposal follows a recently completed, thorough review of the company's business, prospects and industry outlook. Consistent with its fiduciary duties, the Board conducted a review of the proposal, in consultation with independent financial and legal advisors and against the Board's recently completed internal analysis. Following this comprehensive review, the Board unanimously determined that the proposal is highly opportunistic and significantly undervalues Blackbaud. As such, the Board determined that the Clearlake proposal is not an appropriate basis for engagement and is not in the best interest of stockholders.

08:30 EDT Siyata Mobile enters collaboration with CrisisGo - Siyata Mobile announced it is collaborating with CrisisGo to introduce next generation, cellular-based paging services for use by emergency response personnel. Together, CrisisGo's emergency communication system and the Siyata SD7 handset offer a smart, simple and safe paging replacement solution to equip first responders and healthcare system personnel with innovative solutions that enhance emergency response capabilities. The CrisisGo Paging Services solution works seamlessly across both cellular and WiFi networks, breaking geographical limits and providing richer and more reliable capacities for more timely and more reliable emergency communications.

08:22 EDT Point Biopharma expects cash to fund operations into 2026 - Cash, cash equivalents and investments were $541.3 million as of December 31, 2022, which is anticipated to fund operations into fiscal 2026.

08:21 EDT Zoom Video announces expansion of Zoom IQ, to use OpenAI - Zoom Video Communications announced the expansion of Zoom IQ. The company also announced it will use OpenAI to bolster its unique federated approach to AI based on flexibility. "Zoom has long built AI solutions into our products to empower customers to be more productive," said Smita Hashim, chief product officer at Zoom. "We are excited to bring many more capabilities with new large language models. Our unique approach to AI will give customers the flexibility they want and help significantly improve collaboration and customer relations."

08:18 EDT Genetic Technologies Multi-Risk test now includes three new diseases - Genetic Technologies announces the US launch of three new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine, all from the one simple saliva sample. This launch is in line with phase 2 rollout plan for the geneType Multi Risk-Test. The expanded panel now includes: Highlights: Melanoma, Pancreatic Cancer and Atrial Fibrillation - broadening of the utility to 9 serious diseases. Expanded panel is now available population wide for all ethnicities to doctors and their patients in the U.S.1. Multi-Test now provides a stratification assessment of a person's risk profile for six cancers, two cardiovascular diseases and a metabolic disease - for a total of 7 diseases for men and 8 for women. The Multi-Test is available to adults of all ethnicities, starting at the age of 302.

08:16 EDT Organogenesis applauds findings from the Office of Inspector General - Organogenesis Holdings applauds the findings by the Office of the Inspector General, OIG, of the U.S. Department of Health and Human Services, HHS, that transitioning all skin substitute products to average sales price, ASP, -based payments has the potential to substantially reduce Medicare Part B expenditures. In the report, entitled "Some Skin Substitute Manufacturers Did Not Comply with New ASP Reporting Requirements," OIG concluded Centers for Medicare and Medicaid Services could potentially save tens of millions of dollars per quarter if it uniformly used the ASP payment methodology for all skin substitutes. "CMS has made progress in the last six months by expanding the number of skin substitutes that are being paid on the basis of ASP," said Gary Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. Gillheeney added, "ASP-based payments are an important step in stabilizing the skin substitute market and creating a level-playing field. This complements the previous action by the FDA requiring certain injectable tissue products be taken off the market and proceed down a biologics license application pathway."

08:14 EDT G Medical Innovations, MiCare Path announce joint collaboration - G Medical Innovations and MiCare Path announced a collaboration to incorporate MiCare Path's solutions and G Medical Innovations' solutions. As part of the collaboration, G Medical Innovations' hardware devices will be integrated with MiCare's software platform and visualization tools to provide remote patient monitoring services. Under the terms of the agreement, the Company will be responsible for the server integration of its devices into MiCare's platform. MiCare will be responsible for all support and information technology integration pertaining to their patient application. The agreement has a term until December 31, 2024, unless terminated earlier, and will automatically renew for one year thereafter.

08:13 EDT Terns Pharmaceuticals appoints Kuriakose as CMO of Terns oncology - Terns Pharmaceuticals (TERN) announced the appointment of Emil Kuriakose, M.D. as chief medical officer, CMO, of Terns oncology, effective May 1, 2023. Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences (CALA), where he most recently was serving as chief medical officer.

08:11 EDT Delcath Systems: FDA accepts NDA resubmission for Hepzato Kit - Delcath Systems announced that the U.S. FDA has accepted Delcath Systems' new drug application resubmission for Hepzato Kit seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma. The FDA also communicated to Delcath that they consider the submission a complete class 2 response and the PDUFA date for the resubmission is August 14, 2023.

08:10 EDT Baudax Bio announces results from interim analysis of Phase 2 BX1000 trial - Baudax Bio announced results from the second preplanned interim analysis of its Phase 2 trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery. The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia. The primary efficacy endpoint is the proportion of patients meeting criteria for Good or Excellent intubating conditions using a standardized scale. Additionally, the clinical trial is evaluating the safety and tolerability profile of BX1000 and rocuronium in this patient population. The second preplanned interim analysis evaluated the intubating conditions in 41 patients in four cohorts, with each cohort having a minimum of 10 evaluable patients. Results showed that all 41 subjects were observed to have met the criteria for Good or Excellent intubating conditions at 60 seconds. Actual intubation of 40 of the subjects occurred at 60 seconds and 1 subject at 90 seconds. Study treatments were generally well tolerated, with no occurrence of severe or serious adverse events, and one patient experienced a treatment-emergent adverse event that was determined to be possibly related to study treatment. This blinded interim analysis did not result in the decision to drop any of the four study groups nor any decision to adjust planned study enrollment number. "With data from 50% of the planned total enrollment for this trial, these results provide us with confidence that BX1000, combined with our reversal agent BX3000, may provide more precise control of neuromuscular paralysis for surgical patients and have the potential to improve on total time of blockade and reversal compared to available agents," said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. "Importantly, this data set includes subjects from a recently activated second clinical site, and provides an early indication that these results can be replicated in broader clinical use. We anticipate completing enrollment in this trial soon, and announcing top line results in late April or early May."

08:09 EDT Oxbridge launches offering of DeltaCate Re tokenized reinsurance security - Oxbridge Re Holdings announced the launch of its offering of a tokenized reinsurance security, DeltaCat Re, by its new wholly-owned subsidiary SurancePlus.The DeltaCat Re token will indirectly represent fractionalized interests in reinsurance contracts, with each token representing one preferred share of SurancePlus. These reinsurance contracts will be underwritten by Oxbridge Re's reinsurance subsidiary, Oxbridge Re NS Limited, and the proceeds from the sale of the tokens and underlying preferred shares will be used to purchase one or more participating notes of Oxbridge Re NS, with such notes representing an interest in collateralized reinsurance contracts underwritten by Oxbridge Re NS. The DeltaCat Re Tokens are being offered to accredited investors in the United States by SurancePlus under Rule 506(c) of SEC Regulation D and to non-US investors pursuant to Regulation S of the US Securities Act 1933, as amended. Token holders will receive the right to a return on the investment from the performance of the underlying reinsurance contracts of Oxbridge Re NS. Assuming no casualty losses to properties reinsured by Oxbridge Re's reinsurance subsidiaries, DeltaCat Re token investors are expected to receive a return on the original purchase price of the tokens of up to 196% after 3 years. Investor capital will be co-invested alongside ceding insurers' premiums to fully collateralize underwritten reinsurance contracts.

08:07 EDT Aspen University executes amendment to September 2022 Consent Agreement - Aspen Group announced that Aspen University entered into an Amendment to the September 2022 Consent Agreement with the Arizona Board of Nursing that permits the teach-out of the BSN Pre-licensure program to continue. The company said, "On the evening of March 23, 2023, Aspen University and the Arizona Board of Nursing signed an Amendment to the September 2022 Consent Agreement that permits the teach-out of the BSN Pre-licensure program to continue. On behalf of the Pre-licensure students and university administration, we are appreciative to the Board for the opportunity to move forward. Aspen is committed to working closely with the Board, our Consultant and Ombudsperson to ensure that the program "provides minimum instruction and learning opportunities, including clinical opportunities, to meet basic standards of educational practice and legal requirements," as required by the Consent Agreement. We are thankful to be able to establish a process by which we can work cooperatively with the Board to address any concerns about the program they may have."

08:06 EDT DarioHealth announces new contract with nationwide Pharmacy Benefits Manager - DarioHealth announced a new contract with a leading nationwide Pharmacy Benefits Manager operating in 50 states to provide Dario's digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023. Through the new contract, the PBM will replace an existing digital diabetes solution with Dario's proven cardio metabolic digital therapeutic. Dario's solution joins a growing roster of digital health solutions for the PBM, one of the top ten digitally-enabled PBM platforms in the country. Members who are currently users of the PBM's digital diabetes offering will be transitioned to Dario upon launch, which is expected to generate revenue in the second quarter and grow significantly through the rest of 2023. Post-launch, Dario's solutions will be part of the PBM offering to their recent and future customer additions.

08:05 EDT LyondellBasell, EEW sign LOI for potential advanced waste sorting - LyondellBasell and EEW Energy from Waste, a company in thermal waste treatment in Europe recently signed a letter of intent. The LOI includes exploring a potential long-term strategic partnership to extract and recycle plastics out of incineration waste streams. This proposed collaboration would potentially include construction of waste pre-sorting facilities at or near EEW incineration plants to remove plastics from waste streams bound for incineration, and investment in advanced sorting facilities to further sort and refine the plastic that has been removed. This collaboration supports the new LyondellBasell strategy to invest in advanced sorting infrastructure to produce plastic waste-based feedstocks, grow its Circular and Low Carbon Solutions business, and deliver on its value creation ambitions.

08:04 EDT Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact - Vertex Pharmaceuticals (VRTX) and Crispr Therapeutics (CRSP) announced that they have entered into a new non-exclusive licensing agreement for the use of Crispr Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes, or T1D. Under this agreement, Vertex will pay Crispr Therapeutics $100M up-front for non-exclusive rights to Crispr Therapeutics' technology for the development of hypoimmune gene-edited cell therapies for T1D. Crispr Therapeutics will be eligible for up to an additional $230M in research and development milestones and receive royalties on any future products resulting from this agreement.

08:03 EDT Luokung Technology signs shares subscription agreement with COIG - Luokung Technology announced that it has signed a shares subscription agreement with a strategic investor CHINA ORIENT SMART ECOTECH INVESTMENT GROUP LIMITED, pursuant to which the company agreed to issue a total of 5,469,019 restricted ordinary shares for an aggregate of $220M of strategic investment. The closing of the investment is in two tranches. The first tranche of $22M is expected be within 30 working days from the date of the Share Subscription Agreement, and the remaining $198M is expected to be within 60 days thereafter. COIG is to receive ordinary shares with a six-month sales restriction, and unregistered shares come with the right to be exchanged for equity of independent operating subsidiaries of the company within 24 months from the closing.

08:02 EDT Ocugen announces FDA approval for enrollment in OCU400 Phase 1/2 trial - Ocugen announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial. "This approval moves us one step closer in our efforts to bring OCU400, a novel gene-agnostic modifier gene therapy, to market as a potential life-changing treatment for children afflicted with inherited retinal diseases, such as RP and LCA," noted Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer. "This approval further demonstrates the consistent, positive, and timely progress we are making with the Phase 1/2 trial in adult patients. Since a significant number of individuals in the pediatric age group are diagnosed with RP and LCA, it is very important for us to cover this age group in our clinical trials." Enrollment of adult RP patients in the Phase 1/2 trial is complete-per protocol-and enrollment continues among patients with LCA. The Company plans to initiate the Phase 3 trial near the end of 2023.

07:52 EDT Camping World to acquire Carbon Emery RV, terms undisclosed - Camping World announced an agreement to acquire Carbon Emery RV. This acquisition includes two dealerships conveniently located along historic US Route 6 between Provo and Interstate 70. It is anticipated to close in the second quarter of 2023 and will increase the company's Utah location count to six.

07:43 EDT Onex announces change to MVS amendment proposal - Onex announced a change to the Multiple Voting Shares amendment proposal for shareholder consideration at the company's next Annual Meeting of Shareholders. As previously announced in connection with Onex' leadership succession plan, shareholders will be asked to consider an amendment which would add a sunset provision to the current voting entitlement of the MVS. Following consultation with shareholders, the proposed sunset provision will be reduced to a period of three years, from a period of five years as previously communicated. If shareholders approve the proposal, an "Event of Change" will be deemed to have occurred three years after the effective date of the Articles Amendment even if Mr. Schwartz is still Chair and still holds more than 5,000,000 Subordinate Voting Shares.

07:42 EDT Entourage Health launches CBD chewing gum, signs union group to Starseed - Entourage Health announced the expansion of its medical portfolio with the launch of a new CBD chewing gum available to Starseed Medicinal patients on the Company's medical platform.The Company has further developed its medical product portfolio by launching a new CBD chewing gum formulated to provide a rapid onset of CBD with 20 mg per unit. Cannabis-infused gum is made using CBD isolate in partnership with NordicCan The sugar-free gum is naturally flavoured with eucalyptus-lemon-mint, providing a controlled release of cannabinoids conveniently and discreetly. Entourage is also pleased to announce it has added a new union group to its full-service, proprietary medical cannabis program in partnership with leading benefits provider Union Benefits - the administrator of union group benefits to over 12,000 members.

07:41 EDT Intelligent Bio's Intelligent Fingerprinting selected by A & F Sprinklers - Intelligent Bio Solutions announced that A & F Sprinklers has selected INBS's Intelligent Fingerprinting Drug Screening System to support its random drug testing activities across its operations. The drug screening system analyzes fingerprint sweat to screen for recent drug use, including cannabis, cocaine, opiates, and methamphetamine. The portable system will enable A & F Sprinklers HR team to conduct simple, non-intrusive testing anytime and almost anywhere. "An increasing number of organizations are finding random drug testing to be highly effective in deterring drug abuse in the workplace, which is a clear safety hazard to employees," said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. "It's great to see businesses like A & F Sprinklers now extending this approach to their entire workforce. We're pleased they have chosen our Intelligent Fingerprinting solution as an efficient and convenient platform for their drug testing initiatives."

07:40 EDT Unity Biotechnology announces results from Phase 2 ENVISION study of UBX1325 - UNITY Biotechnology announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration, AMD, who were not achieving optimum benefit with their ongoing anti-VEGF therapy. UBX1325 treatment generally maintained visual acuity for 6 months, with a majority of patients not requiring any anti-VEGF rescue. Patients in the every 8-week aflibercept arm had an early and unexpected gain of 3.5 letters at week 2 which was mostly maintained for the duration of the study. As a result of the strength on the control arm, the study did not meet the non-inferiority threshold compared to aflibercept through 24 weeks. Phase 2 ENVISION data through 24 weeks: UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis; Patients treated with UBX1325 had a mean change from baseline in BCVA of -0.8 ETDRS letters at 24 weeks compared to +3.1 ETDRS letters in the aflibercept control arm; Patients treated with UBX1325 had a mean change from baseline in CST of +87.3 microm at 24 weeks compared to +30.5 microm in the aflibercept control arm; 52% of UBX1325-treated patients went at least 24 weeks without receiving anti-VEGF treatment; 92% of UBX1325-treated patients achieved a maximal anti-VEGF treatment-free interval of 12 weeks or longer; The ENVISION study did not meet the non-inferiority margin of -4.5 letters compared to aflibercept with an 85% confidence interval.

07:36 EDT Verano Holdings announces simplification of capital structure - Verano Holdings has simplified its capital structure by completing the conversion of all its outstanding Class B proportionate voting shares into Class A subordinate voting shares, resulting in one class of outstanding shares. Each PV Share was converted into 100 SV Shares pursuant to the terms of the Company's Articles. The rights and preferences of the SV Shares and the PV Shares are the same, except that the converted PV Shares were entitled to economic and voting rights 100 times the economic and voting rights of the SV Shares, which formed the basis for the conversion ratio of 100 SV Shares per PV Share. The SV Shares are listed on the Canadian Securities Exchange under the symbol "VRNO" and are also quoted for trading in the U.S. on the OTCQX under the symbol "VRNOF". The PV Shares were not listed or quoted for trading. As of March 24, 2023, post conversion, Verano had 341,774,840 SV Shares outstanding.

07:31 EDT Hertz CFO to leave company, Alexandra Brooks named interim CFO - Hertz announced that it has appointed Alexandra Brooks, its Chief Accounting Officer, as interim CFO, effective April 1. Brooks will replace Kenny Cheung, who is leaving the company to pursue another professional opportunity in a different industry. Hertz is initiating a formal search process for the selection of its permanent CFO. Cheung will remain at the company until April 14 to support the first quarter financial closing process and ensure an orderly transition to Brooks.

07:20 EDT Broadwind names Jeanette Press to board of directors - Broadwind (BWEN) announced the appointment of Jeanette Press to its Board of Directors, effective March 22, 2023. With the appointment of Press, the Board returned its size to seven members, six of whom are independent. Press will serve as a member of the Board effective immediately, and the Board has determined to nominate Press for re-election as a director at the 2023 annual meeting of stockholders. She will also serve as a member of both the Audit and the Governance/Nominating committees of the Board. Press served as the Chief Financial Officer, Controller and Principal Accounting Officer for CMC Materials (CCMP) until CMC's merger in July 2022.

07:18 EDT Pitney Bowes issues letter to shareholders regarding director nominees - Pitney Bowes issued a letter to Pitney Bowes shareholders in connection with the company's 2023 Annual Meeting of Shareholders to be held on May 9. All Pitney Bowes shareholders of record as of the close of business on March 10 will be entitled to vote at the Annual Meeting. The letter said in part: "Your vote at the upcoming Annual Meeting of Pitney Bowes on May 9, 2023 (the "Annual Meeting") is more important than ever. We urge you to support your Board by voting the GOLD proxy card today "FOR" all Pitney Bowes nominees as well as Hestia nominee Katie May. As you know, Hestia Capital ("Hestia"), is seeking to gain control of the Board of Directors (the "Board") and remove our Chief Executive Officer (CEO) in an unnecessary proxy contest, which jeopardizes our strategic progress over the past decade. Hestia has made an ever-changing series of demands, failed to articulate any coherent strategic thesis, and has yet to present a replacement CEO candidate. Hestia's entire conduct suggests that the election of its slate would destabilize the Company, to the detriment of our shareholders and the future of Pitney Bowes. In its attempts to garner votes, Hestia has recently promoted a series of misleading and inaccurate narratives regarding our Board, management team, the strategic direction of our Company, as well as their own slate of director nominees and their qualifications. We encourage all shareholders to disregard Hestia's falsehoods and learn the actual facts from the Company... Lastly, we have sought an amicable resolution with Hestia over months of engagement, including by offering three new directors, which we have effectively delivered through the appointments of Darrell Thomas and Steven D. Brill, as well as the recommendation of Katie May. Despite this, Hestia has continued to change its demands erratically and has yet to fully articulate an actionable, long-term strategy or plan for the Company. We firmly believe ceding ANY further seats to Hestia would not be in the best interest of the Company and our shareholders. Unsurprisingly, notwithstanding its repeated promises since December, Hestia has yet to present a replacement CEO candidate, meaning shareholders are left to wonder who Hestia would have lead the Company and execute the critical last phase of our transformation to catalyze shareholder value... The Board of Directors of Pitney Bowes urges shareholders to protect their investment and vote "FOR" all the nominees recommended by the Pitney Bowes Board on the GOLD proxy card. All Pitney Bowes shareholders of record as of the close of business on March 10, 2023 will be entitled to vote at the Annual Meeting."

07:17 EDT Gorilla announces partnership with Lanner, Hailo - Gorilla Technology announced a significant partnership with Lanner and Hailo to deliver the E-300 Edge AI Appliance, with an industry-leading price to performance ratio for robust video analytics. Developed through a collaboration with Lanner and Hailo, the E-300 is capable of processing up to 24 channels of real-time, multiple video analytics streams using an entry-level CPU, which ordinarily can only handle 4 channels at the edge. "Through our collaboration with Lanner & Hailo, Gorilla continues to provide Edge AI Appliances that offer outstanding value in terms of price and performance," said Gorilla's Chief Innovation Officer, Dr. Rajesh Natarajan. "We believe this comprehensive solution will expedite the adoption of video analytics and streamline Edge AI deployments at scale. We feel privileged to collaborate with Lanner and Hailo and remain dedicated to delivering customer success."

07:15 EDT Palantir, C3.ai among 18 contractors selected for $900M Space Force contract - Space Systems Command's Battle Management Command, Control and Communications Program Executive Office said late Friday it will award a $900M indefinite delivery/indefinite quantity contract to 18 contractors to provide data software services that directly support warfighter needs. "All Contractors were chosen on a best-value basis, with a heavy emphasis on their commercial software solution and current accreditation or plan/ability to obtain accreditation," the agency said in a statement. Among the contractors selected were Palantir (PLTR), C3.ai (AI), BAE Systems (BAESY) and Oracle (ORCL). Reference Link

07:14 EDT EyePoint completes enrollment in oversubscribed Phase 2 DAVIO 2 trial - EyePoint Pharmaceuticals completed enrollment in the Phase 2 "Durasert and Vorolanib in Ophthalmology 2" clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration. The trial exceeded its original target of 144 patients, enrolling a total of 160 patients. All patients were previously treated with a standard-of-care anti-VEGF therapy and were randomly assigned to one of two doses of EYP-1901 or to an aflibercept on-label control. Topline data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD is anticipated in Q4 2023.

07:12 EDT Winnebago announces definitive agreement to acquire Lithionics Battery - Winnebago Industries announced that it has reached a definitive agreement to acquire Lithionics Battery, a lithium-ion battery solutions provider to recreational equipment and specialty vehicle markets. The addition of Lithionics will provide Winnebago Industries with enhanced technological and engineering capabilities to offer consumers more differentiated products with innovative electrical solutions, as well as bring strategic sourcing benefits and secure a critical area of its supply chain. Terms of the deal were not disclosed. "The addition of Lithionics enhances Winnebago Industries' ability to develop unique and diverse battery solutions across our portfolio, advancing our overall electrical ecosystem, driving organic growth and supply chain security, reinforcing our technological competitive advantage and allowing us to capitalize on consumer preferences for fully immersive, off-the-grid outdoor experiences," said Winnebago Industries President and Chief Executive Officer Michael Happe. "Lithionics' talented employees bring a unique familiarity with our business and the broader outdoor recreation space, as well as share a commitment to quality and safety that fits seamlessly with our culture of excellence. We see significant opportunity to expand the use of their efficient energy solutions within our own portfolio, to continue to grow relationships with other existing customers and to explore new market applications. Through these applications, we expect Lithionics will enhance Winnebago Industries' margin profile over the near- and long-term and create value for our shareholders, employees and consumers. We look forward to working with Steve and his team to integrate their unique platform of electrical capabilities." After the transaction closes, which is expected within Winnebago Industries' third fiscal quarter, subject to customary closing conditions, Tartaglia and the current Lithionics management team will continue to lead the business from its headquarters in Clearwater, Florida. Lithionics will operate as a wholly owned subsidiary of Winnebago Industries.

07:11 EDT Cyclerion Therapeutics receives U.S. FDA orphan drug designation for zagociguat - Cyclerion Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to zagociguat for the treatment of mitochondrial diseases. "Orphan drug designation underscores the FDA's recognition of zagociguat's potential promise as a first-ever therapy for patients with MELAS, a rare, genetic mitochondrial disease," said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion. "Cyclerion is working expeditiously to advance this potential treatment to help address the immense unmet needs of patients with MELAS, a patient population in desperate need of therapies."

07:09 EDT Amicus announces European Commission approval for Pombiliti - Amicus Therapeutics announced that the European Commission, EC, has granted approval for Pombiliti, a long-term enzyme replacement therapy, ERT, used in combination with miglustat for adults with late-onset Pompe disease, LOPD. The Company has submitted the previously requested analytical testing for miglustat, the enzyme stabilizer component of AT-GAA. The Committee for Medicinal Products for Human Use, CHMP, opinion for miglustat is expected in the second quarter of 2023. "Late-onset Pompe disease is a rare, neuromuscular disorder that can have devastating consequences for patients and their families. The European Commission approval for Pombiliti is another major step towards bringing this much needed, new treatment for all adults living in the EU with late-onset Pompe disease. It is the realization of the work of so many individuals and teams dedicated to the mission of improving the lives of people living with Pompe disease," said John F. Crowley, Executive Chairman of Amicus Therapeutics.

07:04 EDT Codiak to pursue asset sale through voluntary Chapter 11 process - Codiak BioSciences announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects to consummate a sale of the entire business or its core assets as soon as reasonably practicable. In connection with the filing, Codiak has appointed Paul Huygens, Principal at Province, LLC, as Chief Restructuring Officer. Mr. Huygens will oversee the business and its restructuring process, working to execute the Company's business strategy and conduct a value-maximizing sale process. Mr. Huygens brings deep experience in managing complex financial and operational restructurings, including providing interim management services to preserve and maximize value. The Company's executive management team, including Dr. Williams, Linda C. Bain Chief Financial Officer and Treasurer, David Mauro, M.D., Ph.D. Chief Medical Officer Sriram Sathyanarayanan, Ph.D. Chief Scientific Officer, and Nicole Barna Senior Vice President, Human Resources, will be departing the Company effective April 7; Dr. Williams will remain on the Board. Yalonda Howze Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary will be departing the Company on April 4. Konstantin Konstantinov, Ph.D. Chief Technology Officer will remain with the Company. The Company will be filing various "First-Day" motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without disruption to its ordinary course operations. Codiak expects these motions to be approved within the first few days of the case. Codiak is represented in this matter by Young Conaway Stargatt & Taylor, LLP as legal advisors, and Province, LLC as financial advisor and provider of interim management services.

07:02 EDT ATI Physical Therapy announces partnership with McDonald's All American Games - ATI Physical Therapy (ATIP) announced an exclusive partnership with the McDonald's (MCD) All American Games. Under the two-year agreement, ATI becomes the Official Physical Therapy Partner for the Games, which features the country's premier high school boys and girls basketball players annually in March. ATI Physical Therapy will provide four dedicated ATI Sports Medicine athletic trainers during the showcase, providing 24/7 medical coverage to the 48 players to help prevent, evaluate and treat sports injuries.

07:01 EDT Microsoft, Internews, USAID to develop Media Viability Accelerator - Internews, Microsoft and the U.S. Agency for International Development announced a new public-private partnership to develop a Media Viability Accelerator to help independent news outlets become more financially sustainable. The announcement, made in advance of the 2023 Summit for Democracy, illustrates a shared commitment among government, business and civil society to shore up democracy's fourth estate. The Media Viability Accelerator is a web-based platform that will help news media become more financially sustainable by accessing solutions and market insights to inform effective business strategies. Participating media outlets will, free of charge, learn from a community of peers, access a multilingual tool that visualizes media performance data, and receive actionable daily alerts based on thousands of market and media sources.

06:52 EDT Spire Global awarded IDIQ contract by NOAA - Spire Global has been awarded an Indefinite Delivery Indefinite Quantity contract by the National Oceanographic and Oceanic Administration to compete for orders under a $59M ceiling. The award is part of NOAA's Commercial Weather Data Program's Radio Occultation Data Buy II. The contract commenced on March 27, 2023 and will run until March 26, 2028. Spire will provide NOAA with near-real-time RO data that consists of vertical profiles of atmospheric measurements, including pressure, humidity and temperature across all points of the globe, as well as ionospheric measurements. The data will be used for NOAA's operational weather forecasts, space weather models and climate research, among other applications.

06:50 EDT BioNTech sees FY23 CapEx EUR500M-EUR600M

06:49 EDT CVS Health expects to complete Signify Health acquisition around March 29 - CVS Health (CVS) announced it expects to complete its acquisition of Signify Health (SGFY) on or around March 29, subject to the satisfaction or waiver of the remaining customary closing conditions set forth in the merger agreement. The companies entered into a definitive agreement in September 2022 under which CVS Health announced it would acquire Signify Health for $30.50 per share in cash for a total transaction value of approximately $8B. Upon completion of the acquisition, Signify Health will continue to operate as a payor-agnostic business as part of CVS Health.

06:46 EDT Novartis says Kisqali Phase 3 NATALEE trial met primary endpoint at interim - Novartis today announced topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali plus endocrine therapy, or ET, in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence. The Independent Data Monitoring Committee recommended stopping the trial early as the primary endpoint of invasive disease-free survival, or iDFS, has been met. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III EBC regardless of nodal involvement. Per the NATALEE study protocol, patient follow-up will continue to evaluate long-term outcomes, including overall survival. "The positive topline results from NATALEE represent a major milestone in our ambition to expand the benefits of Kisqali to patients with earlier stages of breast cancer, building on the heritage of this effective treatment in HR+/HER2- metastatic breast cancer," said Shreeram Aradhye, M.D., President, Global Drug Development and Chief Medical Officer, Novartis. "These data have the potential to be paradigm-shifting for patients at risk of recurrence, including those with no nodal involvement, who have limited well-tolerated options to prevent recurrence. Our teams are working on submissions to health authorities around the world with the hope to bring Kisqali to many more patients diagnosed with breast cancer."

06:14 EDT Brookfield Renewable, EIG Consortium to acquire Origin Energy for $18.7B - A consortium comprised of Brookfield Renewable Partners (BEP), together with its institutional partners and global institutional investors GIC and Temasek, and MidOcean Energy, an LNG company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, has entered into a Scheme Implementation Deed with Origin Energy Limited to acquire 100% of the company's shares. The Scheme values Origin at an enterprise value of $18.7B. The purchase price of $8.91 per share represents a 53.4% premium to the company's unaffected share price. The Origin Board has stated that it is unanimously recommending that Origin shareholders vote in favour of the Scheme in the absence of a superior proposal, and subject to an independent expert concluding the Scheme is in the best interests of shareholders. Upon closing of the transaction, Brookfield, its institutional partners and investors will own Origin's Energy Markets business, Australia's largest integrated power generator and energy retailer. MidOcean will separately own Origin's Integrated Gas segment including its upstream gas interests and the 27.5% stake in Australia Pacific LNG. MidOcean has entered into an agreement to on-sell a 2.49% interest in APLNG to ConocoPhillips (COP). ConocoPhillips, already a 47.5% owner in APLNG, is the current downstream operator and intends to take over upstream operatorship of APLNG. In addition to its institutional and investor partners, Brookfield is also working with Reliance Industries as a strategic partner to assess areas of collaboration in renewable energy in the context of the transaction. Brookfield is pursuing this acquisition through the Brookfield Global Transition Fund I, which is the largest private fund in the world focused on the transition to net zero. Brookfield Renewable, which has significant available liquidity, expects to invest up to US$750 million, which will be funded through a mix of corporate debt, upfinancings of existing hydro assets and proceeds from asset recycling initiatives. EIG is pursuing the acquisition of Origin's Integrated Gas business through MidOcean Energy, an LNG company formed and managed by EIG to create a diversified, 'pure play' integrated global LNG portfolio of high-quality operating LNG projects with strong, long life cash flows. This acquisition would represent a continuation of MidOcean's business strategy and would build upon MidOcean's Australian presence, having recently entered into a definitive agreement with Tokyo Gas to purchase interests in four operating Australian LNG projects. EIG is among the largest specialist investors in energy and infrastructure globally and has had an established presence in Australia since 2000.

06:08 EDT BrainStorm announces FDA ADCOM to review NurOwn BLA - BrainStorm announced that the FDA will hold an Advisory Committee Meeting, or ADCOM, to discuss the company's Biologics License Application, or BLA, for NurOwn for the treatment of amyotrophic lateral sclerosis, or ALS. Given the goal to proceed to an ADCOM as expeditiously as possible, BrainStorm requested that the Center for Biologics Evaluation and Research utilize the FDA's File Over Protest procedure and has filed an amendment to the BLA which responds to most of the outstanding questions the FDA has posed. "The FDA provided us with more than one path to an ADCOM for NurOwn. Our goal has always been to make NurOwn available to people living with ALS as quickly as possible, therefore we chose the File Over Protest pathway since this offered the fastest path to an ADCOM and regulatory decision relative to other pathways provided by the FDA," said Chaim Lebovits, President and CEO of BrainStorm. "The ALS community needs additional treatment options now, and we firmly believe our data support regulatory approval of NurOwn. We are grateful to the FDA for the opportunity to have the clinical evidence supporting NurOwn reviewed."

06:04 EDT Frontier Communications announces new partnership with YouTube TV - Frontier announced a new partnership with YouTube TV that gives consumers exactly what they deserve - blazing-fast, reliable fiber internet bundled together with live and on-demand TV content all on a single bill. Frontier is proud to expand its un-cable offerings with the launch of integrated billing with YouTube TV, which has over 5M subscribers and trialers in the U.S. In 2021, Frontier announced a partnership with YouTube TV to give customers the performance of a superior internet connection and the content of a best-in-class live TV service. Now, Frontier and YouTube TV are making it even more convenient by introducing a single billing option.

05:29 EDT ConocoPhillips to purchase additional 2.49% interest in APLNG for $500M - ConocoPhillips announced through its Australian subsidiary that it plans to become upstream operator of Australia Pacific LNG, or APLNG, following the closing of EIG's transaction with Origin Energy. In connection with this announcement, ConocoPhillips has agreed to purchase up to an additional 2.49% shareholding interest in APLNG for $0.5B, subject to customary adjustments. ConocoPhillips currently holds a 47.5% APLNG shareholding interest and will own up to 49.99% of APLNG upon closing. Both the assumption of upstream operatorship and the shareholding acquisition are dependent on EIG closing its transaction with Origin. EIG's transaction with Origin and ConocoPhillips' shareholding acquisition are subject to Australian regulatory approvals and other customary closing conditions. ConocoPhillips' full-year 2022 production from APLNG was approximately 136 thousand barrels of oil equivalent per day. The transaction is expected to close in early 2024. The effective date of the transaction will be July 1, 2022.

05:20 EDT Incyte announces Japanese MHLW approval of Pemazyre - Incyte announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, has approved Pemazyre, a selective fibroblast growth factor receptor, or FGFR, inhibitor, for the treatment of myeloid/lymphoid neoplasms, or MLNs, with FGFR1 fusion. MLNs are a rare, aggressive group of cancers characterized by an over-production of myeloid cells, or bone tissue, with the tendency to rapidly progress to an acute myeloid leukemia, or AML.

05:12 EDT Elliot will not proceed with Salesforce director nominations - Salesforce and Elliott Investment Management issued a joint statement regarding the company's 2023 annual meeting of stockholders and related director elections. In light of the company's previously announced "New Day" multi-year growth framework, fiscal year 2023 results, fiscal year 2024 transformation initiatives, Elliott decided not to proceed with director nominations, and Salesforce and Elliott have committed to continue the working relationship they have developed together. Marc Benioff, Chair and CEO of Salesforce, said, "I have thoroughly enjoyed getting to know Jesse and the Elliott team over the last few months, and I am grateful for Jesse's mindful and constructive ideas. I look forward to continuing my relationship with Jesse and the Elliott team." Salesforce's upcoming annual meeting will proceed in the ordinary course. Salesforce stockholders are not required to take any action at this time.

04:30 EDT First Citizens acquires deposits and loans of Silicon Valley Bank - The Federal Deposit Insurance Corporation entered into a purchase and assumption agreement for all deposits and loans of Silicon Valley Bridge Bank (SIVB) by First Citizens Bank & Trust Company (FCNCA). The 17 former branches of Silicon Valley Bridge Bank will open as First Citizens Bank & Trust Company on Monday, March 27. Depositors of Silicon Valley Bridge Bank will automatically become depositors of First Citizens Bank. All deposits will continue to be insured by the FDIC up to the insurance limit. The transaction included the purchase of about $72B of Silicon Valley Bridge Bank's assets at a discount of $16.5B. Approximately $90B in securities and other assets will remain in the receivership for disposition by the FDIC. In addition, the FDIC received equity appreciation rights in First Citizens BancShares common stock with a potential value of up to $500M. The FDIC and First-Citizens entered into a loss-share transaction on the commercial loans it purchased of the former Silicon Valley Bridge Bank, National Association. The FDIC as receiver and First-Citizens Bank will share in the losses and potential recoveries on the loans covered by the loss-share agreement. The loss-share transaction is projected to maximize recoveries on the assets by keeping them in the private sector. $20 billion. The exact cost will be determined when the FDIC terminates the receivership. Reference Link